Brought to you by 
Millendo gets $49.5mm in financing concurrent with OvaScience merger closing
10 Dec 2018
Executive Summary
Concurrent with the closing of its reverse merger with OvaScience Inc., Millendo Therapeutics Inc. raised $49.5mm in a financing from Great Point Partners, New Enterprise Associates, Frazier Healthcare Partners, Roche Venture Fund, Innobio (managed by Bpifrance), Osage University Partners, Altitude Life Science Ventures, Adams Street Partners, and Longwood Fund. Jefferies and Leerink Partners were the placement agents. Following the merger, Millendo will become a publicly traded entity.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Millendo gets $49.5mm in financing concurrent with OvaScience merger closing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice